South San Francisco-based Threshold Pharmaceuticals $THLD says that its mid-stage trials for its cancer drug tarloxotinib proved to be a bust, and it’s now restructuring the company as a result. The company – which saw its shares plunge 43% this morning – plans to shift focus to another effort adding evofosfamide to immune checkpoint inhibition. “Stewart M. Kroll, the Company’s Chief Operating Officer, and the members of the biostatistics and data management group will be departing the company,” says the biotech.
Boston-based SQZ, another in a string of spinouts from the lab of MIT’s Bob Langer, has rounded up a $16 million Series B. NanoDimension and Polaris Partners led the round, with participation from other existing and new investors.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription